超薄支架药物洗脱支架术后3-6个月与12个月双联抗血小板治疗比较:HOST-IDEA随机临床试验
HOST-IDEA随机试验在韩国37个中心纳入2013例接受超薄 struts 第三代药物洗脱支架PCI的患者,随机比较3-6个月与12个月DAPT。主要终点净不良临床事件在3-6个月组为3.7%,12个月组为4.1%,达到非劣效(绝对风险差-0.4%,单侧95%CI -∞%至1.1%,P<0.001)。靶病变失败与大出血无显著差异。
要点
- 超薄 struts 第三代DES术后3-6个月DAPT净不良临床事件非劣于12个月DAPT。
- 靶病变失败(HR 0.98,95%CI 0.56-1.71)与大出血(HR 0.82,95%CI 0.41-1.61)无显著差异。
- 各亚组净不良临床事件的治疗效应一致。
核心结论
- 在接受第三代超薄 struts 药物洗脱支架PCI的患者中,3-6个月DAPT对净不良临床事件非劣于12个月DAPT。
研究设计与样本
- 开放标签随机试验,韩国37个中心,纳入接受Orsiro可降解聚合物西罗莫司洗脱支架或Coroflex ISAR无聚合物西罗莫司洗脱支架PCI的患者,排除ST段抬高型心肌梗死。
- 共2013例患者随机分配至3-6个月DAPT组(n=1002)或12个月DAPT组(n=1011),平均年龄65.7±10.5岁,男性1487例(73.9%),急性冠脉综合征1110例(55.1%)。
主要发现
- 主要终点净不良临床事件(心源性死亡、靶血管心肌梗死、临床驱动的靶病变血运重建、支架血栓或BARC 3或5型大出血的复合终点)在12个月时3-6个月组37例(3.7%),12个月组41例(4.1%)。
- 非劣效性检验达到:绝对风险差-0.4%(单侧95%CI -∞%至1.1%),非劣效P<0.001。
- 靶病变失败风险比0.98(95%CI 0.56-1.71,P=0.94),大出血风险比0.82(95%CI 0.41-1.61,P=0.56),均无显著差异。
- 各亚组净不良临床事件的治疗效应一致。
临床怎么用
- 对于使用第三代超薄 struts 药物洗脱支架且无ST段抬高型心肌梗死的PCI患者,可考虑3-6个月DAPT替代12个月DAPT。
- 抗血小板药物选择由医生酌情决定。
局限性
- 需进一步研究以将结果推广至其他人群。
- 需确定3-6个月DAPT的理想方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited data are available on short-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention using third-generation drug-eluting stents with ultrathin struts and advanced polymer technology. We investigated whether 3- to 6-month DAPT was noninferior to 12-month DAPT after implantation of drug-eluting stents with ultrathin struts and advanced polymer technology. METHODS: We performed an open-label, randomized trial at 37 centers in South Korea. We enrolled patients undergoing percutaneous coronary intervention using the Orsiro biodegradable-polymer sirolimus-eluting stents or the Coroflex ISAR polymer-free sirolimus-eluting stents. Patients with ST-segment-elevation myocardial infarction were excluded. Patients were randomly assigned to receive either 3- to 6-month or 12-month DAPT after percutaneous coronary intervention. The choice of antiplatelet medications was at the physician's discretion. The primary outcome was a net adverse clinical event, a composite of cardiac death, target vessel myocardial infarction, clinically driven target lesion revascularization, stent thrombosis, or major bleeding, defined as Bleeding Academic Research Consortium type 3 or 5 at 12 months. The major secondary outcomes were target lesion failure, a composite of cardiac death, target vessel myocardial infarction, clinically driven target lesion revascularization, and major bleeding. RESULTS: A total of 2013 patients (mean age, 65.7±10.5 years; 1487 males [73.9%]; 1110 [55.1%] presented with acute coronary syndrome) were randomly assigned to 3- to 6-month DAPT (n=1002) or 12-month DAPT (n=1011). The primary outcome occurred in 37 (3.7%) patients in the 3- to 6-month DAPT group and 41 (4.1%) in the 12-month DAPT group. The noninferiority of the 3- to 6-month DAPT group to the 12-month DAPT group was met (absolute risk difference, -0.4% [1-sided 95% CI, -∞% to 1.1%]; P<0.001 for noninferiority). There were no significant differences in target lesion failure (hazard ratio, 0.98 [95% CI, 0.56-1.71], P=0.94) or major bleeding (hazard ratio, 0.82 [95% CI, 0.41-1.61], P=0.56) between the 2 groups. Across various subgroups, the treatment effect of 3- to 6-month DAPT was consistent for net adverse clinical event. CONCLUSIONS: Among patients undergoing percutaneous coronary intervention using third-generation drug-eluting stents, 3- to 6-month DAPT was noninferior to 12-month DAPT for net adverse clinical event. Further research is needed to generalize this finding to other populations and to determine the ideal regimen for 3- to 6-month DAPT. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02601157.
引用
- Han, Hwang, Yang, et al. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial. Circulation. 2023. PMID: 36871230. doi:10.1161/CIRCULATIONAHA.123.064264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。